Compare MSM & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSM | MIRM |
|---|---|---|
| Founded | 1941 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.4B |
| IPO Year | 1996 | 2019 |
| Metric | MSM | MIRM |
|---|---|---|
| Price | $90.27 | $88.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $91.00 | ★ $114.67 |
| AVG Volume (30 Days) | 489.6K | ★ 641.3K |
| Earning Date | 04-08-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $3,363,817,000.00 | $19,138,000.00 |
| Revenue This Year | $5.96 | $24.61 |
| Revenue Next Year | $5.23 | $21.75 |
| P/E Ratio | $98.27 | ★ N/A |
| Revenue Growth | ★ 4.99 | N/A |
| 52 Week Low | $68.10 | $36.88 |
| 52 Week High | $96.99 | $109.28 |
| Indicator | MSM | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 40.14 |
| Support Level | $82.32 | $72.17 |
| Resistance Level | $93.15 | $107.51 |
| Average True Range (ATR) | 2.38 | 4.14 |
| MACD | -0.60 | -2.22 |
| Stochastic Oscillator | 39.08 | 12.14 |
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.